Comprehensive protein profiling of synovial fluid in osteoarthritis following protein equalization

M.J. Peffers † *, B. McDermott †, P.D. Clegg †, C.M. Riggs ‡

† Comparative Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Leahurst, Chester High Road, Neston, Wirral, CH64 7TE, UK
‡ Hong Kong Jockey Club, Equine Hospital, Sha Tin Racecourse, New Territories, Hong Kong

Article info

Received 12 November 2014
Accepted 16 March 2015

Keywords:
Synovial fluid
equalization
Osteoarthritis
S100-A10
Neopeptide

Objective: The aim of the study was to characterise the protein complement of synovial fluid (SF) in health and osteoarthritis (OA) using liquid chromatography mass spectrometry (LC-MS/MS) following peptide-based depletion of high abundance proteins.

Design: SF was used from nine normal and nine OA Thoroughbred horses. Samples were analysed with LC-MS/MS using a NanoAcquity™ LC coupled to an LTQ Orbitrap Velos. In order to enrich the lower-abundance protein fractions protein equalisation was first undertaken using ProteoMiner™. Progenesis-QI™ LC-MS software was used for label-free quantification. In addition immunohistochemistry, western blotting and mRNA expression analysis was undertaken on selected joint tissues.

Results: The number of protein identifications was increased by 33% in the ProteoMiner™ treated SF compared to undepleted SF. A total of 764 proteins (462 with ≥2 significant peptides) were identified in SF. A subset of 10 proteins were identified which were differentially expressed in OA SF. S100-A10, a calcium binding protein was upregulated in OA and validated with western blotting and immunohistochemistry. Several new OA specific peptide fragments (neopeptides) were identified.

Conclusion: The protein equalisation method compressed the dynamic range of the synovial proteins identifying the most comprehensive SF proteome to date. A number of proteins were identified for the first time in SF which may be involved in the pathogenesis of OA. We identified a distinct set of proteins and neopeptides that may act as potential biomarkers to distinguish between normal and OA joints.

© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

Osteoarthritis (OA) is a joint disease characterised by alterations in the chondrocytes and loss of cartilage extracellular matrix (ECM)¹, leading to biomechanical failure of articular cartilage. The molecular mechanisms involved in OA are not fully understood, with few currently validated markers for disease diagnosis and progression. Delayed diagnosis precludes preventive or timely therapeutic interventions. These limitations could be surmounted by enhanced knowledge of articular tissue metabolism and homeostasis.

Synovial fluid (SF) is located in joint cavities and comprises a serum filtrate with additional contributions from surrounding tissues. As it is in direct contact with the OA-affected tissues it has been implicated as a contributor to OA pathophysiology. It also represents a potential source of disease-specific proteins that could both aid in the understanding of the pathogenesis of joint disease and act as disease biomarkers.

To date a number of mass spectrometry (MS)-based proteomic studies have been performed on both normal² and diseased³–⁵ SF, with a variety of MS techniques⁴–⁶. In common with serum, SF contains many high-abundant proteins (HAPs) with concentrations exceeding other proteins by estimated ten-orders of magnitude. Removal of HAPs aids in the detection of the lower abundance proteins which may be important in both OA pathogenesis and biomarker discovery. Immunoaffinity depletion has been used to remove these HAPs⁵,⁷; however large proteins, such as albumin, frequently act as carriers for other proteins which may themselves be significant⁸. Another method of compressing the dynamic range of protein but also enabling the entire proteome to be maintained is...
peptide-based depletion\textsuperscript{11}. The method employs combinatorial hexapeptide ligand libraries immobilized on a solid phase matrix and has been used in serum proteomic studies\textsuperscript{11}. This is the first time this approach has been used in SF proteomics.

The horse provides an accepted model for the study of arthropathies\textsuperscript{2,12,13} as it suffers similar clinical joint diseases to those seen in man\textsuperscript{14-16}.

In this study we designed an innovative workflow to study normal and OA SF proteomic signatures. We used a well-documented cohort of skeletally mature horses, peptide-based depletion dynamic compression, LC-MS/MS with a high mass resolution instrument and label-free quantification. Additionally we identified several novel disease-associated peptide fragments (neopeptides).

**Methods**

All chemicals were supplied by Sigma unless otherwise stated.

**SF sampling and procurement**

SF, cartilage, subchondral bone and synovial membrane from the metacarpophalangeal joints of nine normal male \(\pm\) standard deviation (5.1 \(\pm\) 0.5 years) and nine OA (6.5 \(\pm\) 0.4 years) castrated male Thoroughbred horses at post-mortem. Samples were collected under the regulations of the Hong Kong Jockey Club with owner consent and stored at \(-80^\circ\)C. OA diagnosis was based on macroscopic\textsuperscript{17}, histological (modified Mankin)\textsuperscript{18} and synovitis scoring\textsuperscript{19} undertaken on joint tissues.

**SF preparation and protein depletion with ProteoMiner\textsuperscript{TM}**

SF (1 ml) was treated with 1 \(\mu\)g/mL of hyaluronidase\textsuperscript{5}. The supernatant was centrifuged through a 0.22 \(\mu\)m cellulose acetate membrane (Costar Spin-X, Corning, Tokyo, Japan) to remove insoluble material. Protein concentrations of SF were determined by Bradford assay (Thermo Scientific, Rockford, IL, USA).

For peptide-based depletion, 5 mg SF was bound to its own spin column containing ProteoMiner\textsuperscript{TM} Small Capacity beads (Bio-Rad Laboratories, Hemel Hempstead, UK) with on-bead trypsin digestion.

**1-D SDS PAGE**

Following ProteoMiner\textsuperscript{TM} treatment of one sample the eluate along with the flow-through (containing depleted proteins) and a sample of native SF were analysed by one dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis (1D-SDS-PAGE)\textsuperscript{20} to assess quantitative/qualitative differences in protein profiles.

**In-solution tryptic digestion and MS**

Following in-situ tryptic digestion on ProteoMiner\textsuperscript{TM} beads samples were treated with 1\% (w/v) RapiGest (Waters, Manchester, UK) for 10 min at 80 °C in 25 mM ammonium bicarbonate. To determine the effect of protein equalization of SF, equivalent protein from one sample of SF (undepleted sample) was digested by in-solution tryptic digestion\textsuperscript{11}. LC-MS/MS analysis was performed on 2 \(\mu\)l aliquots of tryptic peptides equivalent to 1:10 dilution of the total digest using a 2 \(h\) gradient on a NanoAcquity\textsuperscript{™} ultra-performance LC (Waters, Manchester, UK) on line to an LTQ-Orbitrap-Velos (Thermo-Fisher Scientific, Hemel Hempstead, UK) as previously described\textsuperscript{22}.

**Database search and protein identification**

Raw spectra were converted to mascot generated files (mgf) (Proteome Discoverer software (Thermo, Hemel Hempstead, UK)). The resulting mgf files were searched against the Equus caballus database; Ensembl database for horse (Equus caballus; EquCab2.56.pep, (ftp://ftp.ensembl.org/pub/current_fasta/equus_caballus/pep/) using an in-house Mascot server (Version 2.3.01) (Matrix Science, London, UK). Search parameters used were: enzyme; trypsin, peptide mass tolerances, 10 ppm; fragment mass tolerance, 0.6 Da; 1+, 2+ and 3+ ions; missed cleavages, 1; instrument type, ESI-TRAP. Modifications included were: fixed carbamidomethyl cysteine and variable; oxidation of methionine, lysine, proline.

**Label-free quantification**

The Thermo raw files of the acquired spectra from in-solution tryptic digests were analysed by the Progenesis\textsuperscript{™} LC-MS software (Version 4, Nonlinear Dynamics)\textsuperscript{21}. The top three spectra for each feature was exported from Progenesis-QI\textsuperscript{TM} and utilized for peptide identification against the E. caballus database. Search parameters used were: 10 ppm peptide mass tolerance and 0.6-Da fragment mass tolerance; one missed cleavage allowed; fixed modification, carbamidomethylation; variable modifications, methionine oxidation, proline oxidation, and lysine oxidation. To maximize the number of quantifiable proteins but simultaneously use an acceptable false discovery rate (FDR), the peptide matches above an identity threshold were adjusted to give an FDR of 1\% before the protein identifications being re-imported into Progenesis-QI\textsuperscript{TM}. Mascot determined peptides with ion scores of 20 and above, and only proteins with at least one unique peptide ranked as the top candidate were considered and analysed with only unique peptides being included. Statistical analysis was performed using transformed-normalized abundances for one-way analysis of variance (ANOVA). All peptides (with Mascot score >23 and P < 0.05) of an identified protein were included, and the protein P-value (one-way analysis of variance) was then performed on the sum of the normalized abundances for all runs. Adjusted ANOVA values of \(P < 0.05\) and additionally regulation of >2-fold or <0.5-fold were regarded as significant.

**Neopeptide identification**

For neopeptide determination, MS data from the in-solution tryptic digests of normal and OA SF were analysed\textsuperscript{22}. Filters for inclusion of neopeptides were as previously described\textsuperscript{22}. Patterns of fragmentation were determined for aggrecan, biglycan, decorin, fibromodulin, and cartilage oligomeric matrix protein (COMP).

**Protein network analysis**

Gene ontology (GO) was undertaken on the complete list of proteins identified in SF using the Panther Classification System version 9.0 (www.pantherdb.org)\textsuperscript{23} and Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.7\textsuperscript{14}.

**Western blotting validation of S100A10 abundance**

All validation studies were undertaken with an independent cohort but from the same population and with similar age ranges and macroscopic, Mankin’s and synovitis scores. In order to validate the increased S100A10 abundance in OA SF, 50 \(\mu\)g total protein from normal and OA donors was used in western blot analysis\textsuperscript{25} using rabbit polyclonal to S100A10 (1:100 dilution, ABIN1386030,
Antibodies online, Aachen, Germany) and a horseradish peroxidase conjugated goat anti-rabbit secondary antibody at 1:2000 and Western Lightning™ and Western Lightning Plus Chemiluminescence reagents (Perkin Elmer, Beaconsfield, USA). Blots were imaged using VisionWorksLS image acquisition software package and band densities were analysed using ImageJ 1.42.

**Immunohistochemistry of S100A10**

Immunohistochemistry of cartilage and synovial membrane samples for S100A10 was undertaken using the primary antibody anti-S100A10 at 1:100 in blocking solution. The secondary antibody was a polyclonal anti-rabbit (Z0196, Dako UK Ltd., Ely, UK) at 1:100. No staining was observed in control experiments carried out with omission of the primary antibody and substitution with non-immune rabbit IgG (Abcam, Cambridge, UK). Digital image analysis was undertaken using ImageJ using the ‘threshold-color’ method.

**RNA extraction and gene expression analysis**

Cartilage, subchondral bone and synovial membrane from the metacarpophalangeal joint of selected normal (n = 8) and OA (n = 3) donors was collected into RNAlater and RNA extracted. M-MLV reverse transcriptase and random hexamer oligonucleotides (both Promega, Southampton, UK) were used to synthesize cDNA from 1 µg RNA in a 25 µl reaction. PCR was performed on 1 µl 10× diluted cDNA, employing a final concentration of 300 nM of each primer in 20 µl reaction volumes on an ABI 7700 Sequence Detector using PrimerDesign 2X PrecisionTM SYBR Green Mastermix (Primers Design, Southampton, UK) using exon-spanning primers (Primer Design, Southampton, UK). Relative expression levels were normalised to GAPDH and calculated using the 2^ΔΔCt method.

**Results**

**Macroscopic and histological assessment**

Macroscopic scoring of samples from normal donors was 0 and OA donors were 2.3 ± 0.4SD. Normal donors had a Mankin’s score 0.88 ± 0.45SD and OA donors 13.5 ± 1.45SD. Synovial membrane score from normal donors had a synovitis score of 1.2 ± 0.2SD and OA 1.7 ± 0.25SD.

**Protein depletion of SF**

We used a peptide-based affinity method, to increase identification of low abundance proteins. To investigate the efficiency of this method we resolved non-depleted and depleted samples on a 1-D SDS PAGE gel to compare protein profiles. The peptide-based affinity method reduced the amount of albumin evident by a marked reduction in the 60 kDa albumin band (Fig. 1).

We then compared SF trypsin digests, with and without depletion, using LC-MS/MS and identified 204 proteins and 318 proteins (150 and 243 with significant Mascot score and ≥2 peptides) for native and ProteoMiner™ SF respectively; a 38% increase with ProteoMiner™. A list of proteins is identified in Additional File 1.

**RNA extraction and gene expression analysis**

Cartilage, subchondral bone and synovial membrane from the metacarpophalangeal joint of selected normal (n = 8) and OA (n = 3) donors was collected into RNAlater and RNA extracted. M-MLV reverse transcriptase and random hexamer oligonucleotides (both Promega, Southampton, UK) were used to synthesize cDNA from 1 µg RNA in a 25 µl reaction. PCR was performed on 1 µl 10× diluted cDNA, employing a final concentration of 300 nM of each primer in 20 µl reaction volumes on an ABI 7700 Sequence Detector using PrimerDesign 2X Precision™ SYBR Green Mastermix (Primers Design, Southampton, UK) using exon-spanning primers (Primer Design, Southampton, UK). Relative expression levels were normalised to GAPDH and calculated using the 2^ΔΔCt method.

**Results**

Macroscopic and histological assessment

Macroscopic scoring of samples from normal donors was 0 and OA donors were 2.3 ± 0.1SD. Normal donors had a Mankin’s score 0.88 ± 0.45SD and OA donors 13.5 ± 1.45SD. Synovial membrane score from normal donors had a synovitis score of 1.2 ± 0.2SD and OA 1.7 ± 0.25SD.

**Protein depletion of SF**

We used a peptide-based affinity method, to increase identification of low abundance proteins. To investigate the efficiency of this method we resolved non-depleted and depleted samples on a 1-D SDS PAGE gel to compare protein profiles. The peptide-based affinity method reduced the amount of albumin evident by a marked reduction in the 60 kDa albumin band (Fig. 1).

We then compared SF trypsin digests, with and without depletion, using LC-MS/MS and identified 204 proteins and 318 proteins (150 and 243 with significant Mascot score and ≥2 peptides) for native and ProteoMiner™ SF respectively; a 38% increase with ProteoMiner™. A list of proteins is identified in Additional File 1.
component of 49%). Levels of 10 proteins significantly differed between normal and OA with ≥2 peptides. Six proteins were higher in OA SF and four proteins were lower in OA SF (Table I).

Identification of ECM fragmentation patterns

A catalogue of OA related neopeptides in SF were identified for aggrecan, biglycan, COMP, decorin, fibromodulin, collagen alpha-1(I) and collagen alpha-3(VI) (Table II).

Western blot validation of S100A10

We attempted to verify the results for the two proteins increased in SF with significant q-values; S100A10 and CD109. Unfortunately although antibodies were sourced with predicted reactivity against equine CD109, they did not work. We validated results for S100A10 using immunoblotting which confirmed that S100A10 appeared more abundant in OA SF (Fig. 3).

Characterization of S100A10 in normal and OA cartilage and synovium

Immunohistochemistry analysis of cartilage and synovium from normal and OA horses, using anti-S100A10, was undertaken to determine the strength of expression and its tissue distribution. Immunohistochemistry revealed reduced expression of S100A10 in a homogenous and diffuse pattern in OA synovium compared to normal synovium ($P = 0.02$; Student's $t$ test) [Fig. 4(a) and (c)]. In contrast there was an increase in expression of S100A10 in OA compared to normal cartilage ($P = 0.005$; Student's $t$ test) [Fig. 4(b) and (c)] demonstrated by increased diffuse staining in the tangential and transitional cartilage layers.

S100A10 and CD109 gene expression in joint tissues

To determine whether the difference in S100A10 and CD109 we observed in OA SF was due to local production or represented extra-articular production we undertook gene expression analysis of cartilage, subchondral bone and synovium from normal and OA donors. There were significant tissue and disease differences in the relative gene expression of both CD109 and S100A10 (Fig. 5).
depleted and depleted SF from the same donor using LC-MS/MS. This demonstrated a significant increase (38%) in the number of proteins identified following depletion, agreeing with serum comparative quantitative proteomics studies. We identified 16 of the 20 proteins identified in a previous immunodepletion study in both depleted and undepleted samples. All except two of these had a reduced protein identification Mascot score and protein hit number in the depleted compared to undepleted sample. The change in Mascot generated protein hit number varied. For example albumin was the number one hit in undepleted SF and following treatment with ProteoMiner™ it became the sixth highest hit, whereas transferrin went from the second highest hit to the one hundred and thirty sixth highest hit.

In this study, following ProteoMiner™ treatment, LC-MS/MS with a high mass resolution mass spectrometer and the software Progenesis-Qi™ we report one of the largest number of proteins identified in SF to date. This was despite the presence of HAP (five out of 10 of the top protein hits; complement C3, C4, albumin, apolipoprotein A1 and B) in the results, similar to recent findings in normal porcine SF. This was in part due to Progenesis-Qi™ quantification algorithms that measures all detected peaks and then identifies them, which favours identification of low abundance peptides. A recent publication found 575 proteins using an Isobaric Tags for Relative and Absolute Quantification (iTRAQ) study but this was a comparative study between OA and rheumatoid arthritis (RA) SF. Another study employing multiple fractionation strategies following immunodepletion identified 677 proteins in OA SF.

The diversity of proteins identified in SF included collagenous and non-collagenous ECM proteins, proteases, signalling and immune response proteins. Our data was in agreement with other recent SF proteomics studies confirming the validity of our experimental workflow. Functional distribution of proteins by Panther highlights the breadth of proteins, dominated by intracellular and cell membrane proteins along with plasma proteins in SF. Functional annotation clustering using DAVID identified a number of Kegg pathways enriched. These included complement and coagulation cascade, which can be accounted for by the presence of a number of complement proteins, whilst systemic lupus erythematosus is represented by a number of complement proteins in addition to proteases such as cathepsin and cell surface antigens in SF.

We identified a number of DE proteins in OA. Of these the calcium-binding protein S100A10 (increased in OA SF) plus integral membrane protein 2B and cyclin D binding myb-like transcription factor 1 isoform 1

Discussion

We have performed a comprehensive proteomic analysis of normal and OA SF identifying disease-related alterations to the proteins in OA. LC-MS/MS with high mass resolution instruments has enabled rapid advances in protein profiling of complex body fluids including SF, which enables novel opportunities for gaining disease insight. Using label-free quantification, comparing age-matched controls, we identified a number of DE proteins in OA SF.

In order to minimise the high inter-donor variability previously reported, we used post-mortem samples from a cohort of racehorses which were housed and trained at a single location, were age-matched (young, skeletonly mature), of the same sex and we had access to macroscopically and histological details of the cartilage, subchondral bone, synovium. In addition we had full knowledge of their training and medical histories. This enabled us to choose control donors that had no pathological changes to the age, subchondral bone, synovium. In addition we had full knowledge of the cartilage, and depleted samples by 1D-SDS-PAGE. This confirmed depletion resulted in a more complex visual protein profile together with a reduction in some abundant bands. Furthermore we analysed non-

| Highest mean condition | Accession | Protein | Role | Peptide count | Fold change | ANOVA |
|------------------------|-----------|---------|------|--------------|-------------|-------|
| OA                     | NP_001157339.1 | S100-A10* | Calcium binding protein | 2 | 2.2 | 0.000283 |
|                         | XP_001498093.2 | CD109 antigen | TGF β co-receptor | 9 | 2 | 0.000391 |
|                         | XP_001503419.1 | Phospholipid transfer protein isofrom 1 | Lipid transfer protein | 17 | 2.7 | 0.000981 |
|                         | XP_001916113.1 | Complement component C8 gamma chain | Constituent of the membrane attack complex | 6 | 3.1 | 0.011525 |
|                         | XP_001499636.3 | Collagen alpha-1(I) chain | Fibillar collagen | 22 | 2.8 | 0.045984 |
| Normal                 | XP_001498037.3 | Calcytein-1 | Calcium binding protein | 6 | 2.1 | 0.048534 |
|                         | XP_001904294.3 | Mannan-binding lectin serine protease 2 | Processes amyloid A4 precursor protein | 2 | 2.1 | 0.000676 |
|                         | XP_001504425.1 | Keratin, type II cytokeskeletal 7 | Protease | 3 | 2.2 | 0.006101 |
|                         | XP_001488573.1 | Cyclin D binding myb-like transcription factor 1 isoform 1 | Transcriptional activator | 2 | 6.2 | 0.024012 |

* In addition these proteins had a significant false-discovery rate adjusted P < 0.05.
used for input analysis; only proteins with an FDR of 1% and unique peptides were used for quantification. Additionally, we only targeted proteins for further study if differences had an FDR < 0.05. This was undertaken in order to give the most robust results possible. Other SF studies have used 2D-DIGE3 or spectral counting5,7,8 to quantify, and the different proteomic workflows will account for differences evident between different studies.

Two proteins; CD109 and S100A10 were increased in OA SF with significant FDRs. CD109 is a transforming growth factor-β (TGF-β) co-receptor, released from the chondrocyte cell surface which inhibits TGF-β signalling by promoting TGF-β receptor internalisation and degradation38. CD109 has been detected in the peripheral circulation and SF as a component of CD146-positive lymphocytes in patients with numerous musculoskeletal diseases39. Previously it has also been identified in conditioned media of human articular chondrocytes40, bovine cartilage explants treated with interleukin 1β (IL1-β)41, and human OA cell lysates42. We attempted to undertake western blot validation and IHC in order to verify our MS results and localise CD109 but were unable to find a compatible antibody. Gene expression analysis identified that CD109 was expressed at the greatest level in synovium, followed by subchondral bone and cartilage. Furthermore there was a reduction in gene expression in OA synovium. Normal cartilage function is dependent on a narrow scale of bioactive TGF-β, with aberrations

| Protein          | Amino acid before | Peptide Sequence | Amino acid after |
|------------------|-------------------|------------------|-----------------|
| Aggrecan         | Y                 | TAVEVPNGQPR      | L               |
| Biglycan         | N                 | CIEGMGNPL       | E               |
|                  | P                 | GILSNFVPV       | Y               |
|                  | S                 | PNPSA           | S               |
|                  | V                 | QPATFR          | C               |
| Collagen alpha 1 (I) chain | R       | GPQPQPAVG       | P               |
|                  | R                 | LLLAATALLTHQGEE | G               |
|                  | R                 | LLLAATALLTHQGEE | Q               |
|                  | G                 | APGPSGAR        | G               |
|                  | G                 | PAGPTGAR        | G               |
|                  | E                 | EAGPOQAR        | G               |
|                  | P                 | GADGQPQAK       | G               |
|                  | P                 | QGPSGPQPK       | G               |
|                  | Q                 | AGVMPFQPK       | G               |
|                  | S                 | PENGAPQMQPR     | G               |
|                  | T                 | AGLPGMK         | G               |
| Collagen alpha 3 (VI) chain | K       | RNGIMAFAG       | N               |
|                  | K                 | QPSLETAMS         | A               |
|                  | E                 | DAQEASMALTQR    | G               |
|                  | G                 | SGAVGVPGER      | G               |
|                  | G                 | ETGLDPMLGPLGSDGVSGSPGEPGR | D           |
|                  | L                 | DGISQPAQELK     | R               |
| COMP             | D                 | ACGMQPAR        | T               |
|                  | L                 | AQCAPGSCFPGVACTQTASGARCGP** | C           |
|                  | M                 | NSDGPLAVGYTA    | F               |
|                  | N                 | DDQKTDQDDGRGD   | A               |
|                  | R                 | VRNCNTSPFRECEACPQGYSGTPHEGVG       | A           |
|                  | W                 | AGNGL*          | L               |
|                  | N                 | ALWHTGDATQVR    | L               |
|                  | V                 | MECDAGMMPARTPR  | V               |
| Decorin          | Q                 | MIVVELGTPNLK*   | S               |
|                  | D                 | GDFKNLK         | N               |
|                  | K                 | LKVPGGLA        | D               |
|                  | N                 | GAFGQMK         | K               |
|                  | P                 | GAFTPLV       | L               |
|                  | M                 | PADAPL*         | L               |
| Fibromodulin     | G                 | LCSLRS          | A               |
|                  | R                 | SLREHLHD        | N               |

* denotes found in previous interleukin-1 cartilage explant study.
\[ denotes found in previous a disintegrin with thrombospondin motifs (ADAMTS4) study40.
\[ denotes found in previous matrix metalloproteinase 3 (MMP3) study39.40
\[ denotes previously identified in matrix-assisted laser desorption ionisation study13.
\[ denotes previously identified in equine tendon study22.

Table II
Neopeptides identified in OA SF. Neopeptides shown were identified by Mascot with a significant score in ≥ 2 SF but no normal donors together with a minimum ion score of 20. Amino acids shown in red correspond to the end of the neopeptide corresponding to a potential cleavage site. Amino acids before and after represent those preceding the peptide sequence and following the peptide sequence in the protein.

| Protein | Amino acid before | Peptide Sequence | Amino acid after |
|---------|-------------------|------------------|-----------------|
| Aggrecan| Y                 | TAVEVPNGQPR      | L               |
| Biglycan| N                 | CIEGMGNPL       | E               |
|         | P                 | GILSNFVPV       | Y               |
|         | S                 | PNPSA           | S               |
|         | V                 | QPATFR          | C               |
| Collagen alpha 1 (I) chain | R       | GPQPQPAVG       | P               |
|         | R                 | LLLAATALLTHQGEE | G               |
|         | R                 | LLLAATALLTHQGEE | Q               |
|         | G                 | APGPSGAR        | G               |
|         | G                 | PAGPTGAR        | G               |
|         | E                 | EAGPOQAR        | G               |
|         | P                 | GADGQPQAK       | G               |
|         | P                 | QGPSGPQPK       | G               |
|         | Q                 | AGVMPFQPK       | G               |
|         | S                 | PENGAPQMQPR     | G               |
|         | T                 | AGLPGMK         | G               |
| Collagen alpha 3 (VI) chain | K       | RNGIMAFAG       | N               |
|         | K                 | QPSLETAMS         | A               |
|         | E                 | DAQEASMALTQR    | G               |
|         | G                 | SGAVGVPGER      | G               |
|         | G                 | ETGLDPMLGPLGSDGVSGSPGEPGR | D           |
|         | L                 | DGISQPAQELK     | R               |
| COMP    | D                 | ACGMQPAR        | T               |
|         | L                 | AQCAPGSCFPGVACTQTASGARCGP** | C           |
|         | M                 | NSDGPLAVGYTA    | F               |
|         | N                 | DDQKTDQDDGRGD   | A               |
|         | R                 | VRNCNTSPFRECEACPQGYSGTPHEGVG       | A           |
|         | W                 | AGNGL*          | L               |
|         | N                 | ALWHTGDATQVR    | L               |
|         | V                 | MECDAGMMPARTPR  | V               |
| Decorin | Q                 | MIVVELGTPNLK*   | S               |
|         | D                 | GDFKNLK         | N               |
|         | K                 | LKVPGGLA        | D               |
|         | N                 | GAFGQMK         | K               |
|         | P                 | GAFTPLV       | L               |
|         | M                 | PADAPL*         | L               |
| Fibromodulin | G         | LCSLRS          | A               |
|         | R                 | SLREHLHD        | N               |
outside this range resulting in alterations in TGF-β signalling, resulting in abnormal cartilage function. As CD109 is an important factor in regulating TGF-β signalling, alterations in CD109 within the SF and synovium may play a role in OA pathogenesis. It could be that matrix degradation products or CD109 protein itself released from damaged cartilage in OA and the former of which lead to synovial inflammation may result in reduced CD109 expression in an attempt to promote TGF-β signalling. Further work is required to confirm this hypothesis.

We identified S100A10 in SF for the first time, although increased expression of S100A10 protein has been identified in OA and RA synovial fibroblasts⁴³. The calcium binding protein S100A10, a member of the S100 family retains both intracellular and extracellular functions; including cytokine-like activities⁴⁴. Several members of the S100 family have been identified in human articular cartilage, and their expression is upregulated in both OA and RA (reviewed by Yammani⁴⁵). Other members of the S100 family have been demonstrated in OA⁶,⁸ and RA SF⁶. S100s have been indicated as potential biomarkers of other arthopathies⁴⁶. Interestingly it has been established that some S100 members elicit a catabolic signalling pathway via receptors for advanced glycation end products leading to increased production of matrix-degrading enzymes; matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs), resulting in cartilage degradation and the development of arthritis⁴⁵. S100A10 has been isolated in a complex with Annexin II

---

**Fig. 3.** Increased abundance of S100A10 in OA SF. Representative image of western blot analyses of S100A10 (molecular weight 50 kD) in SF from five OA and three normal donors demonstrates an increase in S100A10 in OA. The blots are representative of eight OA and nine normal samples. Histogram represents mean pixel intensity of OA and normal S100A10 protein bands mean 95%CI, **P = 0.004** (Student’s t test). Units are arbitrary.

**Fig. 4.** Localization of S100A10 in joint tissues from normal and OA horses. Cartilage with underlying subchondral bone and synovium obtained from normal and OA horses were probed with anti-S100A10 antibodies. Quantitative image analysis was undertaken using the ‘Threshold’ method in ImageJ. This ensures that only areas stained with a designated colour are selected for measurement; hence the y-axis in histograms (c) and (d) represents ‘area’. All images were captured at 20× magnification. (a) Synovial membrane sample of representative OA donor (inset) compared with a sample of a normal donor. (b) Cartilage with underlying subchondral bone from a representative OA donor (inset) compared with a normal donor. Histogram represents mean area for (c) synovial membrane for normal (n = 3) and OA (n = 2) and (d) cartilage with underlying bone for normal (n = 4) and OA (n = 3) mean 95%CI together with statistical significance of results (Student’s t test).
(p26) which enables membrane localization of S100A10 by the formation of a heterotetramer (Altt), interacting with plasminogen activator and plasminogen, stimulating its activation47. Through MAPK and NFκβ, Altt induces IL1β, IL6 and tumour necrosis factor (TNF)α and consequently, silencing of S100A10 was demonstrated to reduce the secretion of TNFα, IL1β and IL10 in lipopolysaccharide stimulated chondrocytes48. Thus S100A10 has been proposed as a target for OA therapeutics. In our study we identified an increase in S100A10 protein in cartilage, but a reduction in the synovium in OA using IHC. It is therefore probable that the increase in S100A10 in SF evident in OA is due to an increase in its presence in cartilage, due to cartilage pathology in OA. This is then ‘shed’ into the SF on cartilage breakdown.

We also investigated OA-specific cleavage patterns in the ECM by assessing fragmentation patterns of specific matrix molecules in OA SF. A catalogue of ECM protein fragments, produced by fragmentation of the original peptide by enzymatic cleavage between two amino acids, which we have termed ‘neopeptides’, were identified in this study, and are likely due to specific proteinase cleavage. In our previous studies in equine ageing and diseased tendon we identified both tendinopathy and age-specific neopeptides22. In another study we identified OA related neopeptides in equine cartilage13. In this study all donor ages were coupled to a high mass resolution mass-spectrometer was appropriate for SF proteomics for both discovery and quantification. We discovered a distinct set of proteins that may act as potential bio-markers to distinguish between normal and OA joints. Further investigation postulated a role for S100A10 and CD109 in OA pathogenesis. Finally we also identified a catalogue of neopeptides in SF for the first time which may increase our understanding of OA pathogenesis and act as potential OA biomarkers.

**Conclusion**

We demonstrated our novel workflow technique involving peptide-based equalisation followed by liquid chromatography coupled to a high mass resolution mass-spectrometer was appropriate for SF proteomics for both discovery and quantification. We discovered a distinct set of proteins that may act as potential bio-markers to distinguish between normal and OA joints. Further investigation postulated a role for S100A10 and CD109 in OA pathogenesis. Finally we also identified a catalogue of neopeptides in SF for the first time which may increase our understanding of OA pathogenesis and act as potential OA biomarkers.

**Acknowledgements**

MJP was supported by a Wellcome Trust Veterinary Integrated Research Fellowship (WT088557MA). The study was additionally funded by Liverpool Health Partners and supported by the MRC and Arthritis Research UK as part of the MRC–Arthritis Research UK Centre for Integrated research into Musculoskeletal Ageing (CIMA). We would like to thank Timothy Koh Jia Wei and Valerie Tilstone for their assistance with the immunohistochemistry studies. We thank Dr Aaron Dale for the critical reading of this manuscript.

**Abbreviations**

1D-SDS-PAGE one dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis
2D-DIGE two-dimensional electrophoresis
ADAMTS a disintegrin and metalloproteinase with thrombospondin motifs
ANOVA analysis of variance
COMP cartilage oligomeric matrix protein
DE differential expression
DAVID The Database for Annotation, Visualization and Integrated Discovery
ECM extracellular matrix
FDR false discovery rate
GAPDH glutaraldehyde dehydrogenase
GO gene ontology
HAP high abundance proteins
IL interleukin
LC-MS/MS liquid chromatography tandem mass spectrometry
MGF mascot generated file
MMP matrix metalloproteinases
OA osteoarthritis
PPM parts per million
RA rheumatoid arthritis
RT-PCR real-time polymerase chain reaction

**Fig. 5.** Gene expression at tissue and disease level of CD109 and S100A10. Cartilage, subchondral bone and synovium mRNA levels of (a) CD109, and (b) S100A10 in normal and OA donors. Data are represented as relative gene expression compared to GAPDH. Histograms represent means 95%CI. *P < 0.05, **P < 0.001. Data were evaluated using Student’s t test (normal n = 8, OA n = 3).
SF: synovial fluid
SRM: selected reaction monitoring
TGF: transforming growth factor
TNF: tumour necrosis factor

Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.joca.2015.03.019.

Competing interests
The authors declare that they have no competing interests.

Author's contributions

MJP, conceived the study, carried out most of the laboratory work and bioinformatics analysis, and drafted the manuscript. PDC obtained funding, participated in the design and coordination of the study and helped to draft the manuscript. CMR collected all the samples, participated in the design and coordination of the study, performed histological assessment and helped to draft the manuscript. BM participated in the design and helped to draft the manuscript. All authors read and approved the final manuscript.

References

1. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000;43:1916–26.
2. Bennike T, Ayturk U, Haslauer CM, Froehlich JW, Proffen BL, Barnaby O, et al. A normative study of the synovial fluid proteome from healthy porcine knee joints. J Proteome Res 2014;13:4377–87.
3. Chiaradia E, Pepe M, Tartaglia M, Scoppetta F, D’Ambrosio C, Renzone G, et al. Gambling on putative biomarkers of arthritis and osteochondrosis by equine synovial fluid proteomics. J Proteomics 2012;75:4478–93.
4. Gobezie R, Kho A, Krastins B, Sarracino DA, Thornhill TS, Chase M, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007;9:R36.
5. Mateos J, Lourido I, Fernandez-Puente P, Calamia V, Fernandez-Lopez C, Oreiro N, et al. Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC-MALDI TOF/TOF. J Proteomics 2012;75:2869–78.
6. Baillet A, Trocme C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteome fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford) 2010;49:671–82.
7. Garner BC, Kuroki K, Stoker AM, Cook CR, Cook JL. Expression of proteins in serum, synovial fluid, synovial membrane, and articular cartilage samples obtained from dogs with stifle joint osteoarthritis secondary to cranial cruciate ligament damage and dogs without stifle joint arthritis. Am J Vet Res 2013;74:386–94.
8. Balakrishnan L, Nirujobi RS, Ahmad S, Bhattacharjee M, Manda SS, Renuse S, et al. Protemic analysis of human osteoarthritis synovial fluid. Clin Proteomics 2014;11:6.
9. Zhou M, Lucas DA, Chan KC, Issaq HJ, Petricoin 3rd EF, Liotta LA, et al. An investigation into the human serum “interactome”. Electrophoresis 2004;25:1289–98.
10. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991;354:82–4.
11. Puangpila C, Mayadunne E, El Radi Z. Liquid phase based separation systems for depletion, pre-fractionation, and enrichment of proteins in biological fluids and matrices for in-depth proteomics analysis-an update covering the period 2011–2014. Electrophoresis 2015;36:238–52.
12. Peffers M, Liu X, Clegg P. Transcriptomic signatures in cartilage ageing. Arthritis Res Ther 2013;15:R98.
13. Peffers MJ, Cillero-Pastor B, Eijkel GB, Clegg PD, Heeren RM. Matrix assisted laser desorption ionization mass spectrometry imaging identifies markers of ageing and osteoarthritic cartilage. Arthritis Res Ther 2014;16:R110.
14. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse — a review. Vet J 2006;171:51–69.
15. Innes JF, Clegg P. Comparative rheumatology: what can be learnt from naturally occurring musculoskeletal disorders in domestic animals? Rheumatology (Oxford) 2010;49:1030–9.
16. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res 2012;1:297–309.
17. Kawcak CE, Frisbie DD, Werpy NM, Park RD, McIlwraith CW. Effects of exercise vs experimental osteoarthritis on imaging outcomes. Osteoarthritis Cartilage 2008;16:1519–25.
18. Moskowitz RW. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:1–2.
19. Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller B, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 2006;49:358–64.
20. McLean L, Hurst JL, Gaskell CJ, Lewis JC, Beynon RJ. Characterization of cauxin in the urine of domestic and big cats. J Chem Ecol 2007;33:1997–2009.
21. Peffers MJ, Beynon RJ, Clegg PD. Absolute quantification of selected proteins in the human osteoarthritic secretome. Int J Mol Sci 2013;14:20658–81.
22. Peffers MJ, Thorpe CT, Collins JA, Eong R, Wei TK, Screen HR, et al. Proteomic analysis reveals age-related changes in tendon matrix composition, with age- and injury-specific matrix fragmentation. J Biol Chem 2014;289:25867–78.
23. Mi H, Dong Q, Muruganuajan A, Gaudet P, Lewis S, Thomas PD. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the gene ontology consortium. Nucleic Acids Res 2010;38:D204–10.
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44–57.
25. Chang X, Cui Y, Zong M, Zhao Y, Yan X, Chen Y, et al. Identification of proteins with increased expression in rheumatoid arthritis synovial tissues. J Rheumatol 2009;36:872–80.
26. Zamboulis DE, Senior JM, Clegg PD, Gallagher JA, Carter SD, Milner PI. Distribution of purinergic P2X receptors in the equine digit, cervical spinal cord and dorsal root ganglia. Purinergic Signal 2013;9:383–93.
27. Van Dongen P, Chort I, van der Meulen-de Rooij J, Vrieze E, van Gool RG, et al. Lumen of the syncytium of the equine digit and foot is increased in granulomatous equine foot disease. Equine Vet J 2010;42:504–9.
28. Lee Y, Jeong J, Park Y, Kim J, Lee J, Kim K, et al. Real-time quantitative PCR of the 2(–Delta Delta C(T)) Method. Methods 2001;25:402–8.
30. Yamagiwa H, Sarkar G, Charlesworth MC, McCormick DJ, Bolander ME. Two-dimensional gel electrophoresis of synovial fluid: method for detecting candidate protein markers for osteoarthritis. J Orthop Sci 2003;8:482–90.

31. Dwivedi RC, Krokhin OV, Cortens JP, Wilkins JA. Assessment of the reproducibility of random hexapeptide peptide library-based protein normalization. J Proteome Res 2010;9:1144–9.

32. Marco-Ramell A, Bassols A. Enrichment of low-abundance proteins from bovine and porcine serum samples for proteomic studies. Res Vet Sci 2010;89:340–3.

33. Paulus A, Thulasiram V, Acadameia K, Freeby S, Roth S, Wehr T, et al. Quantitation of Serum and Plasma Proteins after Enrichment of Low Abundance Proteins with the ProteoMiner Protein Enrichment System. In: Technote 5841: Technical Notes 2014.

34. Gonzalez-Iglesias H, Alvarez L, Garcia M, Escribano J, Rodriguez-Calvo PP, Fernandez-Vega L, et al. Comparative proteomic study in serum of patients with primary open-angle glaucoma and pseudoexfoliation glaucoma. J Proteomics 2014;98:65–78.

35. Millioni R, Tolin S, Puricelli L, Sbrignadello S, Fadini GP, Tessari P, et al. High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One 2011;6:e19603.

36. America AH, Cordewener JH. Comparative LC-MS: a landscape of peaks and valleys. Proteomics 2008;8:731–49.

37. Balakrishnan L, Bhattacharjee M, Ahmad S, Nirujogi RS, Renuse S, Subbannayya Y, et al. Differential proteomic analysis of synovial fluid from rheumatoid arthritis and osteoarthritis patients. Clin Proteomics 2014;11:1.

38. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finsson KW, et al. The TGF-beta co-receptor, CD109, promotes internalization and degradation of TGF-beta receptors. Biochim Biophys Acta 2011;1813:742–53.

39. Dagur PK, Tatlici G, Gourley M, Samsel L, Raghavachari N, Liu P, et al. CD146+ T lymphocytes are increased in both the peripheral circulation and in the synovial effusions of patients with various musculoskeletal diseases and display pro-inflammatory gene profiles. Cytom B Clin Cytom 2010;78:88–95.

40. Polacek M, Bruun JA, Elvenes J, Figenschau Y, Martinez I. The secretory profiles of cultured human articular chondrocytes and mesenchymal stem cells: implications for autologous cell transplantation strategies. Cell Transplant 2011;20:1381–93.

41. Stevenson NJ, Addley MR, Ryan EJ, Boyd CR, Carroll HP, Paunovic V, et al. CCL11 blocks IL-4 and GM-CSF signaling in hematopoietic cells and hinders dendritic cell differentiation via suppressor of cytokine signaling expression. J Leukoc Biol 2009;85:289–97.

42. Finnson KW. Principles of Osteoarthritis- Its Definition, Character, Derivation and Modality-Related Recognition. Intech; 2012.

43. Bo GP, Zhou LN, He WF, Luo GX, Jia XF, Gan CJ, et al. Analyses of differential proteome of human synovial fibroblasts obtained from arthritis. Clin Rheumatol 2009;28:191–9.

44. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60:540–51.

45. Yammani RR. S100 proteins in cartilage: role in arthritis. Biochim Biophys Acta 2012;1822:600–6.

46. Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 2012;71:1991–7.

47. MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003;278:25577–84.

48. Song C, Zhou X, Dong Q, Fan R, Wu G, Ji B, et al. Regulation of inflammatory response in human chondrocytes by lentiviral mediated RNA interference against S100A10. Inflamm Res 2012;61:1219–27.

49. Hambach L, Neureiter D, Zeiler G, Kirchner T, Aigner T. Severe disturbance of the distribution and expression of type VI collagen chains in osteoarthritic articular cartilage. Arthritis Rheum 1998;41:986–96.

50. Peffers MJ. Protein and transcriptomic signatures of cartilage ageing and disease. In: Institute of Ageing and Chronic Disease, vol. PhD. Liverpool: University of Liverpool; 2013:340.